NANOTECH RCC Biomarkers
- Conditions
- Renal Cell CancerRenal Cell Carcinoma
- Registration Number
- NCT02923284
- Lead Sponsor
- Washington University School of Medicine
- Brief Summary
The incidence of renal cell carcinoma (RCC or kidney cancer) in men exceeds that of pancreatic cancer or leukemia. In women, the incidence of RCC is similar to that of leukemia, ovarian, or pancreatic cancer; thus, RCC is significant health issue. This study focuses on identifying specific molecules \[biomarkers\] of RCC that can be used to develop a reliable low-cost screening method at the point of service. If successful, our method would provide a diagnostic test to distinguish benign kidney masses from malignant ones, eliminating the need to surgically remove a kidney with a benign tumor.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 407
Patients 18 years of age and older undergoing surgery. Patient samples are divided into 2 groups based on their surgery: Patients with an imaged renal mass, encompassing about 300 patients/year (about 1200 total) of both malignant (about 80-85% of time) and benign (about 15-20% of time), and patients with non-kidney cancers, encompassing about 6,000 patients/year (about 24,000 total),
Age <18 years and prisoners.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Urine AQP1 28 days Assay results will be compared to the pathology report for the excised renal mass and the ICD10 codes.
PLIN2 concentration 28 days Assay results will be compared to the pathology report for the excised renal mass and the ICD10 codes.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Washington University St Louis School of Medicine
🇺🇸Saint Louis, Missouri, United States